Cybin Inc. (NASDAQ:HELP – Get Free Report) shares traded up 8.8% on Tuesday . The company traded as high as $7.82 and last traded at $7.7360. 706,854 shares were traded during mid-day trading, a decline of 32% from the average session volume of 1,035,549 shares. The stock had previously closed at $7.11.
Analysts Set New Price Targets
Separately, TD Cowen assumed coverage on Cybin in a report on Monday, April 13th. They issued a “buy” rating for the company. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cybin currently has a consensus rating of “Buy” and an average price target of $55.00.
Check Out Our Latest Report on Cybin
Cybin Stock Performance
Hedge Funds Weigh In On Cybin
Several hedge funds have recently bought and sold shares of the company. Millennium Management LLC raised its holdings in shares of Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after acquiring an additional 959,448 shares during the last quarter. Bank of America Corp DE boosted its stake in Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after buying an additional 11,790 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its stake in Cybin by 46.7% in the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock worth $63,000 after buying an additional 2,400 shares during the last quarter. 17.94% of the stock is owned by hedge funds and other institutional investors.
About Cybin
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
Further Reading
- Five stocks we like better than Cybin
- Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build
- 2 ETFs to Access the World’s Best-Performing Stock Markets In 2026
- IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story
- Alphabet Is Planning a New AI Chip. Here’s Why It Matters Ahead of Earnings
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
